The Challenge of Immunogenicity in Biologics Drug Development Biologic drug development is a rapidly evolving sector in the biopharmaceutical industry. Biologically-based therapeutic drugs comprise monoclonal antibodies (MAbs), vaccines, recombinant hormones and proteins, antibody-drug conjugates, RNAi, antisense, blood factors, and other large molecules. Although the success of biologics has been demonstrated, there are inherent operational and […]Read More
Author: Piet van der Graaf
Piet has 15 years’ experience working in the pharmaceutical industry at Synthélabo (Sanofi) and Pfizer, where he held leadership positions in Discovery Biology, Pharmacokinetics & Drug Metabolism (PDM) and Clinical Pharmacology/Pharmacometrics. He obtained his PharmD from the University of Groningen, The Netherlands, and a PhD in quantitative pharmacology from King’s College London, UK, and was elected as a Fellow of the British Pharmacological Society. He is also Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology. He brings his considerable skill and experience to our projects and contributes to the strategic development of Certara.